View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals
March 7, 2022

Deals relating to China’s socioeconomic impact decreased significantly in the pharma industry in H2 2021

During second half of 2021, deals relating to China's socioeconomic impact accounted for 10.9% of all deals taking place in the sector.

By Emil Filipov

In the second half of 2021 the number of deals relating to China’s socioeconomic impact decreased significantly by 34.2% from the same period in 2020.

This marks a deceleration in growth from the 28.8% increase in deals that occurred in H1 2021 relative to the same period a year earlier.

GlobalData’s deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During second half of 2021, deals relating to China's socioeconomic impact accounted for 10.9% of all deals taking place in the sector. This represents an increase from the figure of 6.9% in second half of 2020.

GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter.

These themes, of which 'China Impact' is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU